Tri:ChAd:TB
Tri:ChAd:TB is built on the chimpanzee adenovirus serotype 68 vector, expressing Ag85A, TB10.4, and RpfB. These antigens spanning distinct M.tb life-cycle stages. Ag85A wanes after acute infection, whereas TB10.4 remains highly expressed. RpfB is upregulated during dormancy and resuscitation. This vaccine is formulated for respiratory mucosal delivery.
Read MoreMtbΔfbpA
We have developed three live vaccine candidates by knocking out or deleting genes in Mycobacterium tuberculosis H37Rv. We named them as double knockout (DKO), Triple knockout (TKO), and quadruple knockout (QKO). These strains have the following gene deletions: DKO (Mtb∆fbpA-∆sapM), TKO (Mtb∆fbpA-∆sapM-∆zmp1), and (Mtb∆fbpA-∆sapM-∆zmp-∆dosR).
Read MoreSeV986A
Our group utilizes an replication-defective Sendai virus (SeV) as TB vaccine vector, and constructed SeV85AB and SeV986A vaccine. SeV986A expressed a fusion of acute- and latency-stage Mtb antigens (4 antigens). In murine models, it serves as a potent BCG-booster, significantly reducing bacterial burden in both active and latent infection challenges.
Read MoremRNA-Rv1387-Rv0287-Rv1788
The vaccine consists of three antigens delivered with the mRNA platform. Monovalent antigens were cloned into mRNA constructs containing a 5’ cap, 5’ untranslated region (UTR), 3’ UTR, and a polyadenylation signal, subjected to in vitro transcription using N1-methylpseudouridine, and encapsulated in lipid nanoparticles containing ALC-0315, 18:1 (Δ9-Cis) PE (DOPE), cholesterol, and 14:0 PEG2000 PE.
Read MoreChAdOx1.5Ag/MVA.5Ag
ChAdOx1.5Ag is a recombinant, replication deficient chimpanzee adenovirus, expressing the four antigens of the mycobacterium Esx-5a system (PPE15, PE8, EsxI, EsxJ), along with Ag85A. In mice, ChAdOx1.5Ag improved the efficacy of BCG in the lung and spleen, and a further boost with MVA.5Ag further improved efficacy in the spleen. ChAdOx1.5Ag/MVA.5Ag was also promising in non-human…
Read More